Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD300LF drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD300LF ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD300LF Products |
| Gene Delivery | CD300LF Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for flow cytometry and cell-based functional assays. |
View CD300LF Products |
| Benchmark Ab | Anti-CD300LF Recombinant Antibody Recombinant positive control derived from clinical-stage/validated clones. |
View CD300LF Products |
| Validator | CD300LF siRNA Set For knockdown verification in primary myeloid cells or cell lines. |
View CD300LF Products |
| Related Target A | CD300A Inhibitory homolog. Crucial for off-target counter-screening and selectivity profiling. |
View CD300A Products |
| Related Target B | SIRPA Synergistic myeloid checkpoint. Co-targeting CD300LF and SIRP-alpha enhances macrophage-mediated phagocytosis. |
View SIRPA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Cyno/Mouse) | Human, Mouse, and Cynomolgus CD300LF ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily off-target counter-screening | Homologous panel (CD300A, CD300C, CD300E) proteins strictly verified by mass spectrometry to guarantee sequence identity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives in Binding Assays | Validated siRNA included for target-specific knockdown verification in functional assays. |
Live CD300LF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD300LF therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and myeloid-checkpoint-targeted bispecifics. As first-generation immunotherapies reach clinical limits in cold tumors, the next wave of R&D is targeting CD300LF to modulate the immunosuppressive microenvironment of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech Startups, Academic Consortia | Acute Myeloid Leukemia (AML), Solid Tumors | Internalization Assay (Need high-purity, native glycosylated ECD-Fc) |
| Bispecific / Multi-specific | Immuno-oncology Pioneers | Refractory Solid Tumors | Heterodimer Validation & Cross-reactivity (Need diverse CD300 family panels) |
| Antagonistic Monoclonal Antibody | Autoimmune-focused Biopharma | Inflammatory Bowel Disease (IBD), SLE | Ligand Blocking Assays (Need high-affinity monomeric CD300LF) |